Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations

@inproceedings{Papi2016LongTermFP,
  title={Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations},
  author={Alberto Papi and Adel H. Mansur and Tetyana Pertseva and Kirsten Kaiser and Tammy McIver and Birgit Grothe and Sanjeeva Dissanayake},
  booktitle={Journal of aerosol medicine and pulmonary drug delivery},
  year={2016}
}
BACKGROUND A primary goal of asthma management is the reduction of exacerbation risk. We assessed the occurrence of oral corticosteroid-requiring exacerbations (OCS exacerbations) with long-term fluticasone/formoterol therapy, and compared it with the occurrence of similar events reported with other inhaled corticosteroid/long acting β2-agonist (ICS/LABA) combinations. METHODS The occurrence of OCS exacerbations was assessed in two open-label trials of fixed-dose fluticasone/formoterol… CONTINUE READING